Dr. Mazyar Shadman from the University of Washington/Fred Hutchinson Cancer Center and Dr. Danielle Brander from Duke Cancer Institute discuss matching adjusted indirect comparisons (MIACs) for first-line chronic lymphocytic leukemia (CLL) treatment decisions. The discussion explores how these statistical methodologies help compare treatments from different clinical trials when direct head-to-head comparisons are unavailable, acknowledging their limitations while recognizing their value in rapidly evolving treatment landscapes. Key analyses include zanubrutinib (SEQUIOA trial) comparisons with venetoclax-based fixed-duration regimens, CLL14 (venetoclax-obinutuzumab), and AMPLIFY (acalabrutinib-venetoclax). Results consistently favored continuous BTK inhibitor therapy for progression-free survival, particularly after 3 years, while demonstrating favorable safety profiles despite longer treatment exposure. Clinical Considerations: MIACs provide systematic comparisons beyond separate trial evaluations but cannot replace randomized head-to-head trials Anchored analyses (shared control arms) offer stronger evidence than unanchored methodologies Patient goals regarding treatment duration, efficacy priorities, and risk tolerance remain paramount in decision-making Disease markers including IGHV mutation status and TP53 aberrations influence optimal treatment selection between continuous versus fixed-duration approaches
Dr. Mazyar Shadman from the University of Washington and Fred Hutchinson Cancer Center and Dr. Danielle Brander from Duke Cancer Institute introduce their discussion on interpreting matching adjusted indirect comparisons (MIACs) to inform first-line chronic lymphocytic leukemia (CLL) treatment decisions. The focus centers on how recent comparative analyses help clinicians choose between continuous BTK inhibitor therapy versus fixed-duration venetoclax-based therapies in clinical practice.
Dr. Brander discusses the comparison of zanubrutinib from the SEQUOIA trial with fixed-duration venetoclax plus ibrutinib from GLOW and CAPTIVATE studies, examining patient populations and study design relevance.
Dr. Shadman transitions to discussing the second analysis comparing zanubrutinib as continuous therapy versus venetoclax-obinutuzumab fixed-duration regimen, the previously preferred approved fixed-duration option in the United States.
Dr. Brander introduces the third analysis comparing zanubrutinib from SEQUOIA with acalabrutinib plus venetoclax from AMPLIFY, representing an anchored analysis with similar comparison arms showing zanubrutinib association with prolonged progression-free survival when adjusting for baseline characteristics.
Dr. Brander asks about synthesizing comparative analyses and important limitations clinicians should understand when interpreting cross-trial comparisons, including balancing insights with other evidence forms.
